Abselion, an innovative life sciences technology company dedicated to simplifying biomolecule quantification, has announced the establishment of a US subsidiary located at The Engine in Cambridge, Massachusetts. This strategic move aims to foster closer engagement with scientists in North America, in response to the increasing international adoption of its Amperia protein quantification platform.
The new US facility will serve as a formal base for Abselion, enhancing its presence within the North American life sciences ecosystem. This development is expected to facilitate more direct collaboration with academic institutions, biotech firms, and pharmaceutical research teams engaged in biologics characterisation and development workflows.
By establishing a US subsidiary, Abselion seeks to complement its existing collaborations and support the next phase of growth, particularly as interest in the Amperia protein quantification system expands beyond the UK and Europe. The Engine, a Tough Tech incubator and accelerator developed by the Massachusetts Institute of Technology (MIT), offers specialised infrastructure and long-term support for companies in life sciences, biotech, and other transformative technologies. This environment will enable Abselion to effectively align its organisational structure with the geographic distribution of its customer base, allowing for better planning and coordination of activities across North America.
The establishment of a presence in the US will support the introduction and ongoing use of Abselion’s systems, while further enhancing collaboration in the region. Additionally, it underscores the company’s commitment to expanding its global footprint and ensuring that the necessary structures are in place to facilitate future international growth.
Dr Ruizhi Wang, CEO and Founder of Abselion, remarked on the significance of this development: “Our vision is to make high-quality quantification more accessible through closer international collaboration. Establishing a US subsidiary marks an important milestone in Abselion’s growth, strengthening our ability to operate across key life science markets globally while continuing to build on our strong scientific foundation.”
The United States serves as a focal point for advanced biologics research and development. Abselion’s formal presence in this market demonstrates its commitment to supporting the long-term adoption of its protein quantification systems. This strategic location will allow the growing international team to engage more closely with customers and partners as they explore and develop workflows around the Amperia platform.
For more information regarding Abselion’s US site and its Amperia platform, please visit Abselion’s website. Additionally, the team will be present at BPI West from 9–11 March in San Diego, CA, for those interested in learning more about their offerings.
For further inquiries, please contact:
- Dr Michelle Ricketts
- Codon Communications
- Tel: +447789053885
- Email: [email protected]